News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ConMed Corporation (CNMD) Announces Third Quarter 2012 Financial Results



10/25/2012 9:20:35 AM

UTICA, NY--(Marketwire - October 25, 2012) - CONMED Corporation (NASDAQ: CNMD)

  • Sales Increase 5.3%
  • GAAP EPS Increases 10.3%
  • Adjusted EPS Increases 30.3%

CONMED Corporation (NASDAQ: CNMD) today announced financial results for the third quarter ended September 30, 2012.

"CONMED's third quarter results continued the strong earnings and cash flow trends of the first two quarters of the year," commented Mr. Joseph J. Corasanti, President and CEO. "Earnings per share grew 10.3% while earnings per share adjusted for restructuring and acquisition costs increased 30.3% on sales growth of 5.3%. Single-use products continued to perform well, growing 7.6% in constant currency. Capital products were flat on a constant currency basis, an improvement from the 7.5% decline in the first six months of the year. From a strategic standpoint, in the last week of the third quarter, we completed the acquisition of Viking Systems, Inc. providing CONMED with the only stand-alone 3D-HD surgical visualization system cleared for sale in the United States."

As discussed below under "Use of Non-GAAP Financial Measures," the Company presents various non-GAAP adjusted financial measures in this release. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with generally accepted accounting principles ("GAAP"). Please refer to the attached reconciliation between GAAP and adjusted financial measures.

Third Quarter 2012 Financial Highlights:

  • Sales grew to $181.9 million, an increase of 5.3% (organic increase of 1.2%) and an increase of 6.0% on a constant currency basis as compared to the third quarter of 2011.

  • Single-use products comprised 79.7% of total sales and grew 7.0% (7.6% constant currency), while sales of capital products declined 1.1% (0.3% growth constant currency).

  • Diluted earnings per share (GAAP) grew 10.3% to $0.32.

  • Adjusted diluted earnings per share grew 30.3% to $0.43.

  • Adjusted operating margin expanded 50 basis points to 10.2%.

  • GAAP operating margin was 7.8%.

  • Adjusted EBITDA margin expanded 150 basis points to 16.6%.

  • GAAP EBITDA margin was 14.1%.

  • A favorable income tax benefit amounting to $0.05 per share, on an adjusted basis, was recorded due to the conclusion of several tax matters.

  • The Board of Directors declared a quarterly cash dividend of $0.15 per share, which was paid on October 5, 2012.

Nine Months 2012 Financial Highlights

  • Sales grew to $565.9 million, an increase of 4.9% (increase of 0.8% organic) and an increase of 5.1% on a constant currency basis as compared to the first nine months of 2011.

  • Single-use products comprised 80.1% of total revenues and grew 7.8% (increase of 7.9% constant currency), while capital products declined 5.5% (decline of 5.0% constant currency).

  • Diluted earnings per share (GAAP) grew 14.4% to $1.03.

  • Adjusted earnings per share grew 21.9% to $1.28.

  • Adjusted operating margin expanded 50 basis points to 10.4%.

  • GAAP operating margin was 8.5%.

  • Adjusted EBITDA margin expanded 150 basis points to 16.5%.

  • GAAP EBITDA margin was 14.6%.

International sales in the third quarter and first nine months of 2012 were $89.3 million and $283.9 million, or 49.1% and 50.2% of total sales, respectively. The recent volatility in foreign currency exchange rates was mitigated by the Company's currency hedging. Nevertheless, due to unfavorable FX rate changes, sales were lower by $2.2 million in the third quarter and lower by $5.5 million for the first nine months of 2012 than would have been the case using comparable 2011 exchange rates.

Cash provided by operating activities in the third quarter of 2012 amounted to $28.0 million. For the nine months ended September 2012, cash provided by operating activities totaled $61.3 million. As previously disclosed, cash flow in the first quarter of 2012 was reduced by a contribution of $6.5 million to the Company's frozen pension plan and payment of incentive compensation.

As a component of the Company's capital allocation strategy, CONMED has returned value to shareholders through the initiation in early 2012 of a 15-cent quarterly dividend (which provides a yield of approximately 2% based upon the current share price). Further, the Board of Directors has previously authorized share repurchases and the Company has $108.8 million remaining available under such authorizations. It is management's intention, subject to market conditions and provisions of its credit agreement, to repurchase approximately $50 million of CONMED stock over the next six to nine months as an additional means of returning value to the Company's shareholders.

Outlook

"CONMED has generated significant earnings and margin improvement through the first nine months of 2012, even with the lingering effects of a slowly growing world economy. For the fourth quarter of 2012 we expect sales and earnings consistent with previous guidance," continued Mr. Corasanti. "Specifically, we anticipate fourth quarter 2012 sales to approximate $199 - $204 million and adjusted earnings per share to be in the range of $0.48 - $0.52. Based on this outlook for the fourth quarter, we are narrowing our guidance for full year 2012 although it remains within the previously provided wider ranges. We now expect full year 2012 sales of $765 - $770 million and adjusted diluted earnings per share of $1.76 - $1.80."

"As we look forward to 2013, we are cognizant of external headwinds from the continued softness of the world economy causing just modest increases in healthcare utilization, the effects of the 2.3% excise tax on medical devices sold in the United States, and foreign currency exchange rates which are less favorable than the FX rates at which we hedged our sales in 2012. While we believe we will be able to offset these challenges through the introduction of new products and the continuation of our announced cost efficiency programs, the anticipated earnings per share growth in 2013 is expected to be approximately 5% compared to the 15%, which we would normally expect without the headwinds," noted Mr. Corasanti.

"Adjusted earnings per share for 2013 is expected to approximate $1.80 - $1.90 while 2013 sales is expected to be in the range of $785 - $795 million," continued Mr. Corasanti. "Effectively, these external matters have caused us to re-set the base from which management will target earnings growth of approximately 15% annually in-line with our strategic plan."

The sales and earnings forecasts for fourth quarter 2012 and full year 2013 have been developed using September 2012 currency exchange rates and take into account the currency hedges entered into by the Company.

The adjusted estimates for the fourth quarter of 2012 and full year 2013 exclude unusual matters, such as the restructuring costs expected to be incurred in 2012 and 2013 due to the Viking acquisition and the related relocation of surgical video activities from Santa Barbara, California. Additionally, the Company will continue the consolidation of the Tampere, Finland location into United States facilities. Costs related to these consolidation activities are excluded from the estimates above.

Unusual charges

During 2012, the Company purchased Viking Systems, Inc., continued the on-going consolidation of certain administrative functions, transferred additional product lines to its Mexican manufacturing facility and began the consolidation of the Tampere, Finland facility. Also incurred were integration costs relative to the purchase of a distributor in northern Europe and litigation costs associated with a contractual dispute with a former distributor. Expenses associated with these activities, including severance and relocation costs, amounted to $3.1 million, net of tax, in the third quarter of 2012 and $7.2 million net of tax for the nine months. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2012, the Company presently anticipates incurring additional pre-tax restructuring costs of $4.0 - $5.0 million on projects currently in process.

Use of non-GAAP financial measures

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income and adjusted earnings per share because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses adjusted net income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its third quarter 2012 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, October 25, 2012. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through November 5, 2012.

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company's products serve the clinical areas of arthroscopy/sports medicine, minimally invasive surgical visualization, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,400 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company's total sales.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.

CONMED CORPORATION CONSOLIDATED STATEMENTS OF INCOME (in thousands except per share amounts) (unaudited) Three months ended Nine months ended September 30, September 30, ------------------- ------------------- 2011 2012 2011 2012 --------- --------- --------- --------- Net sales $ 172,814 $ 181,885 $ 539,500 $ 565,896 Cost of sales 80,677 82,129 258,452 262,821 Cost of sales, other - Note A 826 1,843 2,566 4,519 --------- --------- --------- --------- Gross profit 91,311 97,913 278,482 298,556 --------- --------- --------- --------- Selling and administrative 68,350 74,064 206,290 222,577 Research and development 7,021 7,077 21,499 21,364 Other expense - Note B - 2,658 792 6,421 --------- --------- --------- --------- 75,371 83,799 228,581 250,362 --------- --------- --------- --------- Income from operations 15,940 14,114 49,901 48,194 Amortization of debt discount 1,131 - 3,338 - Interest expense 1,670 1,345 5,182 4,333 --------- --------- --------- --------- Income before income taxes 13,139 12,769 41,381 43,861 Provision for income taxes 4,928 3,449 15,495 14,277 --------- --------- --------- --------- Net income $ 8,211 $ 9,320 $ 25,886 $ 29,584 ========= ========= ========= ========= Per share data: Net Income Basic $ 0.29 $ 0.33 $ 0.91 $ 1.05 Diluted 0.29 0.32 0.90 1.03 Weighted average common shares Basic 28,348 28,438 28,355 28,265 Diluted 28,546 28,721 28,734 28,621

Note A -Included in cost of sales, other in the three and nine months ended September 30, 2011 are $0.8 million and $2.6 million, respectively, related to the consolidation of our production facilities. For the three and nine months ending September 30, 2012, we incurred $1.8 million and $4.5 million, respectively, related to the consolidation of our production facilities.

Note B -Included in other expense in the nine months ended September 30, 2011 is $0.8 million related to consolidating certain administrative functions at our Utica, New York facility. For the three and nine months ending September 30, 2012, we incurred $1.9 million and $3.4 million, respectively, related to administrative consolidation expense. Also included in other expense in the three and nine months ending September 30, 2012 is $0.7 million in costs associated with the acquisition of Viking Systems, Inc. Included in the nine months ending September 30, 2012 is $0.7 million in costs associated with the acquisition of our former distributor in the Nordic region of Europe and $1.6 million in legal costs associated with a contractual dispute with a former distributor.

CONMED CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (in thousands) (unaudited) ASSETS December 31, September 30, 2011 2012 ------------- ------------- Current assets: Cash and cash equivalents $ 26,048 $ 19,819 Accounts receivable, net 135,641 132,872 Inventories 168,438 165,326 Income tax receivable - 1,295 Deferred income taxes 10,283 11,759 Other current assets 16,314 13,606 ------------- ------------- Total current assets 356,724 344,677 Property, plant and equipment, net 139,187 139,775 Deferred income taxes 2,389 2,713 Goodwill 234,815 256,825 Other intangible assets, net 195,531 192,721 Other assets 6,948 152,077 ------------- ------------- Total assets $ 935,594 $ 1,088,788 ============= ============= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt $ 54,557 $ 1,009 Other current liabilities 76,627 124,534 ------------- ------------- Total current liabilities 131,184 125,543 Long-term debt 88,952 168,437 Deferred income taxes 92,785 106,316 Other long-term liabilities 49,602 86,045 ------------- ------------- Total liabilities 362,523 486,341 ------------- ------------- Shareholders' equity: Capital accounts 244,980 258,183 Retained earnings 354,439 371,267 Accumulated other comprehensive loss (26,348) (27,003) ------------- ------------- Total equity 573,071 602,447 ------------- ------------- Total liabilities and shareholders' equity $ 935,594 $ 1,088,788 ============= ============= CONMED CORPORATION CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS (in thousands) (unaudited) Nine months ended September 30, ---------------------------- 2011 2012 ------------- ------------- Cash flows from operating activities: Net income $ 25,886 $ 29,584 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 31,802 34,770 Stock-based compensation expense 3,714 4,115 Deferred income taxes 11,961 11,752 Increase (decrease) in cash flows from changes in assets and liabilities: Accounts receivable 14,745 6,910 Inventories (10,768) (2,436) Accounts payable 2,285 1,693 Income taxes receivable (payable) 829 (7,996) Accrued compensation and benefits (2,507) (5,235) Other assets (2,897) (2,723) Other liabilities 1,659 (9,171) ------------- ------------- Net cash provided by operating activities 76,709 61,263 ------------- ------------- Cash flow from investing activities: Purchases of property, plant, and equipment (12,672) (15,969) Payments related to business acquisitions, net of cash acquired (72) (82,843) ------------- ------------- Net cash used in investing activities (12,744) (98,812) ------------- ------------- Cash flow from financing activities: Payments on debt (23,451) (54,063) Proceeds of debt - 80,000 Dividend payments from common stock - (8,590) Repurchase of treasury stock (15,021) - Net proceeds from common stock issued under employee plans 5,759 9,414 Other, net (3,148) 5,533 ------------- ------------- Net cash provided by (used in) financing activities (35,861) 32,294 ------------- ------------- Effect of exchange rate change on cash and cash equivalents (638) (974) ------------- ------------- Net increase (decrease) in cash and cash equivalents 27,466 (6,229) Cash and cash equivalents at beginning of period 12,417 26,048 ------------- ------------- Cash and cash equivalents at end of period $ 39,883 $ 19,819 ============= ============= CONMED CORPORATION RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT Three Months Ended September 30, 2011 and 2012 (in thousands except per share amounts) (unaudited) 2011 2012 --------- --------- Reported net income $ 8,211 $ 9,320 --------- --------- Facility consolidation costs included in cost of sales 826 1,843 --------- --------- Administrative consolidation costs included in other expense - 1,940 Viking acquisition costs included in other expense - 718 --------- --------- Total other expense - 2,658 --------- --------- Amortization of debt discount 1,131 - --------- --------- Unusual expense before income taxes 1,957 4,501 Provision (benefit) for income taxes on unusual expenses (715) (1,437) --------- --------- Net income before unusual items and amortization of debt discount $ 9,453 $ 12,384 ========= ========= Per share data: Reported net income Basic $ 0.29 $ 0.33 Diluted 0.29 0.32 Net income before unusual items and amortization of debt discount Basic $ 0.33 $ 0.44 Diluted


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES